Amgen shares fell over the likelihood the biotech’s next potential blockbuster drug will take longer than expected to reach its full sales potential. This week, the California company said the FDA had requested additional data on the proposed osteoporosis drug Prolia. Analysts still hold a positive view of Amgen’s prospects and expect Prolia to be a blockbuster; but rebuilding revenue may take longer than expected.
© Copyright 2009 Globe Newspaper Company.
